Top 10 Biopharma IPOs of January—June 2018
Number of Companies Going Public, and the Amount They Raise, Show Growth
Enabling the Rise of a CRISPR World
As the World Debates Genome Editing Regulations, the Scientific Community Continues the Push to Democratize CRISPR
Cannabinoid-Based Drugs Seek New High, Part II
Developers Anticipate Additional Approvals after FDA Nod for Epidiolex
Blood Protein Linked to Mental Disorders
Consciousness-Aiding Protein Produced by Cells Deep in the Brainstem
David Hercher Ph.D.
David Hercher, Ph.D., Master of Science at Ludwig Boltzmann Institute for Experimental and Clinical Traumatology.
More GEN Content From This Contributor
- GEN Exclusives: Pushing the Right Buttons